vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Neuronetics, Inc. (STIM). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $41.8M, roughly 1.8× Neuronetics, Inc.). On growth, Neuronetics, Inc. posted the faster year-over-year revenue change (85.7% vs -36.9%). Neuronetics, Inc. produced more free cash flow last quarter ($692.0K vs $-6.6M). Over the past eight quarters, Neuronetics, Inc.'s revenue compounded faster (54.9% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology. 

MED vs STIM — Head-to-Head

Bigger by revenue
MED
MED
1.8× larger
MED
$75.1M
$41.8M
STIM
Growing faster (revenue YoY)
STIM
STIM
+122.6% gap
STIM
85.7%
-36.9%
MED
More free cash flow
STIM
STIM
$7.3M more FCF
STIM
$692.0K
$-6.6M
MED
Faster 2-yr revenue CAGR
STIM
STIM
Annualised
STIM
54.9%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
STIM
STIM
Revenue
$75.1M
$41.8M
Net Profit
$-7.2M
Gross Margin
69.4%
52.0%
Operating Margin
-10.4%
-12.1%
Net Margin
-17.2%
Revenue YoY
-36.9%
85.7%
Net Profit YoY
43.2%
EPS (diluted)
$-1.64
$-0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
STIM
STIM
Q4 25
$75.1M
$41.8M
Q3 25
$89.4M
$37.3M
Q2 25
$105.6M
$38.1M
Q1 25
$115.7M
$32.0M
Q4 24
$119.0M
$22.5M
Q3 24
$140.2M
$18.5M
Q2 24
$168.6M
$16.4M
Q1 24
$174.7M
$17.4M
Net Profit
MED
MED
STIM
STIM
Q4 25
$-7.2M
Q3 25
$-2.3M
$-9.0M
Q2 25
$2.5M
$-10.1M
Q1 25
$-772.0K
$-12.7M
Q4 24
$-12.7M
Q3 24
$1.1M
$-13.3M
Q2 24
$-8.2M
$-9.8M
Q1 24
$8.3M
$-7.9M
Gross Margin
MED
MED
STIM
STIM
Q4 25
69.4%
52.0%
Q3 25
69.5%
45.9%
Q2 25
72.6%
46.6%
Q1 25
72.8%
49.2%
Q4 24
74.1%
66.2%
Q3 24
75.4%
75.6%
Q2 24
73.2%
74.0%
Q1 24
72.8%
75.1%
Operating Margin
MED
MED
STIM
STIM
Q4 25
-10.4%
-12.1%
Q3 25
-4.6%
-19.6%
Q2 25
-1.0%
-21.1%
Q1 25
-1.1%
-34.4%
Q4 24
0.6%
-51.0%
Q3 24
1.5%
-41.7%
Q2 24
-4.7%
-51.7%
Q1 24
4.5%
-39.4%
Net Margin
MED
MED
STIM
STIM
Q4 25
-17.2%
Q3 25
-2.5%
-24.3%
Q2 25
2.3%
-26.6%
Q1 25
-0.7%
-39.6%
Q4 24
-56.4%
Q3 24
0.8%
-72.0%
Q2 24
-4.8%
-59.8%
Q1 24
4.8%
-45.2%
EPS (diluted)
MED
MED
STIM
STIM
Q4 25
$-1.64
$-0.10
Q3 25
$-0.21
$-0.13
Q2 25
$0.22
$-0.15
Q1 25
$-0.07
$-0.21
Q4 24
$0.08
$-0.34
Q3 24
$0.10
$-0.44
Q2 24
$-0.75
$-0.33
Q1 24
$0.76
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
STIM
STIM
Cash + ST InvestmentsLiquidity on hand
$167.3M
$28.1M
Total DebtLower is stronger
$65.8M
Stockholders' EquityBook value
$198.9M
$22.4M
Total Assets
$248.0M
$141.6M
Debt / EquityLower = less leverage
2.94×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
STIM
STIM
Q4 25
$167.3M
$28.1M
Q3 25
$173.5M
$28.0M
Q2 25
$162.7M
$11.0M
Q1 25
$164.6M
$20.2M
Q4 24
$162.3M
$18.5M
Q3 24
$170.0M
$20.9M
Q2 24
$163.5M
$42.6M
Q1 24
$156.4M
$47.7M
Total Debt
MED
MED
STIM
STIM
Q4 25
$65.8M
Q3 25
$65.7M
Q2 25
$55.5M
Q1 25
$55.3M
Q4 24
$55.2M
Q3 24
$46.0M
Q2 24
$59.8M
Q1 24
$59.4M
Stockholders' Equity
MED
MED
STIM
STIM
Q4 25
$198.9M
$22.4M
Q3 25
$214.7M
$27.4M
Q2 25
$216.0M
$27.1M
Q1 25
$211.0M
$35.5M
Q4 24
$210.1M
$27.7M
Q3 24
$207.3M
$9.4M
Q2 24
$205.3M
$19.4M
Q1 24
$211.0M
$27.7M
Total Assets
MED
MED
STIM
STIM
Q4 25
$248.0M
$141.6M
Q3 25
$268.2M
$145.5M
Q2 25
$269.3M
$134.7M
Q1 25
$280.0M
$142.0M
Q4 24
$284.2M
$140.9M
Q3 24
$291.2M
Q2 24
$293.5M
$96.8M
Q1 24
$302.8M
$103.8M
Debt / Equity
MED
MED
STIM
STIM
Q4 25
2.94×
Q3 25
2.40×
Q2 25
2.05×
Q1 25
1.56×
Q4 24
1.99×
Q3 24
4.90×
Q2 24
3.08×
Q1 24
2.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
STIM
STIM
Operating Cash FlowLast quarter
$-5.3M
$908.0K
Free Cash FlowOCF − Capex
$-6.6M
$692.0K
FCF MarginFCF / Revenue
-8.8%
1.7%
Capex IntensityCapex / Revenue
1.8%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$-21.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
STIM
STIM
Q4 25
$-5.3M
$908.0K
Q3 25
$12.1M
$-785.0K
Q2 25
$-3.4M
$-3.5M
Q1 25
$3.4M
$-17.0M
Q4 24
$-4.9M
$-8.6M
Q3 24
$9.1M
$-5.4M
Q2 24
$13.1M
$-5.0M
Q1 24
$7.3M
$-12.0M
Free Cash Flow
MED
MED
STIM
STIM
Q4 25
$-6.6M
$692.0K
Q3 25
$10.8M
$-899.0K
Q2 25
$-4.8M
$-3.8M
Q1 25
$1.9M
$-17.2M
Q4 24
$-7.2M
$-8.7M
Q3 24
$7.7M
$-5.8M
Q2 24
$11.1M
$-5.6M
Q1 24
$5.4M
$-12.4M
FCF Margin
MED
MED
STIM
STIM
Q4 25
-8.8%
1.7%
Q3 25
12.0%
-2.4%
Q2 25
-4.5%
-9.9%
Q1 25
1.6%
-53.8%
Q4 24
-6.1%
-38.6%
Q3 24
5.5%
-31.3%
Q2 24
6.6%
-34.0%
Q1 24
3.1%
-71.1%
Capex Intensity
MED
MED
STIM
STIM
Q4 25
1.8%
0.5%
Q3 25
1.5%
0.3%
Q2 25
1.3%
0.7%
Q1 25
1.3%
0.7%
Q4 24
1.9%
0.4%
Q3 24
1.0%
2.1%
Q2 24
1.1%
3.7%
Q1 24
1.1%
2.2%
Cash Conversion
MED
MED
STIM
STIM
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons